GlaxoSmithKline PLC is transforming its culture with a new emphasis on clear decision making and a focus on “smart risk taking”. Speaking at an Endpoints News UKBIO19 event in London, chief scientific officer and president of R&D, Hal Barron said this cultural transformation is already making an impact. In Vivo provides details about how a past, failed, consensus-driven approach to decision making drove his initial efforts to create a cultural change among the company’s 10,000 R&D employees so that each project would have a clear “single accountable decision-maker.” Two years later, Barron reports people noting that he didn’t just talk about a new strategy; it’s actually taking place.